Massachusetts is currently home to 3215 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Physio-Anatomy Clinical Data Collection Study
NCT05312164
Recruiting
This is an on-label clinical study design intended for the collection of three different types of interventional procedural data using FDA-cleared cardiac catheterization technologies and drugs, each used according to its product labeling and standard practice of medicine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Coronary Stenosis
Register for Updates
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
NCT03928288
Recruiting
Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a randomized, double blind clinical trial aimed at repurposing an existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial pro... Read More
Gender:
FEMALE
Ages:
Between 15 years and 40 years
Trial Updated:
03/19/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Endometriosis
Register for Updates
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome
NCT06050122
Recruiting
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Harvard Medical School - Mass Gen (MGH) - Cancer Center - Center for Pediatric Hematology-Oncology, Boston, Massachusetts
Conditions: Gorlin Syndrome
Register for Updates
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
NCT04472338
Recruiting
This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.
Gender:
MALE
Ages:
40 years and above
Trial Updated:
03/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Prostate Carcinoma
Register for Updates
An FMRI Investigation of the Effects of IV Lidocaine on Tinnitus
NCT04192773
Recruiting
This is an exploratory pilot open-label study to identify the signal changes on fMRI of patients with tinnitus and with temporary suppression of the tinnitus with IV lidocaine. Patients will include those with hearing loss (both unilateral and bilateral) and tinnitus, subjects with normal hearing and tinnitus, and control subjects with normal hearing and no tinnitus. Eligible subjects will have functional and subjective data collected at baseline, receive an IV lidocaine infusion, and have funct... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
Conditions: Tinnitus
Register for Updates
Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA
NCT06091098
Recruiting
Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a "classic" model of OSA has been used to describe the disorder, which fails to capture it's complexity. Recently, a model for OSA called drive-dependent OSA was discovered be more prevalent in the OSA population. The drive-dependent subgroup benefits exclusively from increased v... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
03/17/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: OSA
Register for Updates
Lupus Landmark Study: A Prospective Registry and Biorepository
NCT05934149
Recruiting
The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
03/17/2025
Locations: University of Massachusetts Memorial Health, Worcester, Massachusetts
Conditions: Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
Register for Updates
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
NCT05917522
Recruiting
800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: Massachusetts General Hospital: Transplantation, Boston, Massachusetts
Conditions: Kidney Transplant
Register for Updates
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
NCT05819866
Recruiting
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cerebral Adrenoleukodystrophy (cALD)
Register for Updates
Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI
NCT05671874
Recruiting
The goal is to pilot test a highly accessible, web-based, pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogate decision-makers of patients in ICUs with severe acute brain injury (SABI), including those with moderate-severe traumatic brain injury, large hemispheric acute ischemic stroke and intracerebral hemorrhage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: UMass Memorial Hospital, Worcester, Massachusetts
Conditions: Hemorrhagic Stroke, Intracerebral, Acute Ischemic Stroke, Traumatic Brain Injury
Register for Updates
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354
Recruiting
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
Pembrolizumab and Brentuximab Vedotin in Subjects with Relapsed/Refractory T-cell Lymphoma
NCT05313243
Recruiting
This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma) who have received at least one prior therapy. We hypothesize that this combination is effective and will produce an overall response rate of \~55%. Pembrolizumab and brentuximab will be administered for 16 cycles in subjects with responsive disease. Pembrolizumab w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: T-Cell Lymphoma
Register for Updates